Featured Sessions

Pre-registration for each session is not required.
Please come directly to the seminar venue on the day of the event for any seminars you're interested in.　

If you have not yet completed your admission registration, please complete from here.

Powered by Partnership: ITRI × KOTRA

October 2, 2025 (Thursday) 10:00~11:30

[HOS-S2] English Seminar: Global Insights into Medical Device and Healthcare Trends
— Lessons from Taiwan and Korea

[HOS-S2] English Seminar:
Global Insights into Medical Device and Healthcare Trends
— Lessons from Taiwan and Korea

Innovation and Breakthrough in Taiwan’s Smart Healthcare Industry

Eric Y. Chuang
Vice President and General Director,
Biomedical Technology and Device Research Laboratories

Industrial Technology Research Institute (ITRI)

＜Seminar content＞
Taiwan is advancing global health by leveraging its world-class biomedical supply chains, robust healthcare system, and advanced ICT infrastructure. Across 23 leading medical centers, AI and big data are driving telemedicine, smart wards, AI-assisted diagnostics, and clinical decision support, earning recognition such as the 2023 HIMSS Davies Award and the 2024 Digital Health Indicator. At ITRI, the Biomedical Technology and Device Research Laboratories (BDL) integrate diverse technologies to accelerate biomedicine and device innovation, winning five R&D 100 Awards and seven Edison Awards. Through its Biomedical Innovation Interdisciplinary Collaboration Platform and Fast Track Clinical Trials, BDL supports startups, accelerates commercialization, and strengthens Taiwan’s smart healthcare ecosystem.

＜Speaker Profile＞
Education
2015-2017
EMBA, National Taiwan University, Taipei, Taiwan
1991-1997
Sc.D. Cancer Biology, Harvard University, School of Public Health, Boston, MA

Experience
2021-2023
Dean, Office of Academia-Industry Cooperation & Dean, College of Biomedical Engineering & Professor, Master program for Biomedical Engineering, China Medical University, Taichung, Taiwan
2015-present
Deputy Director, Research and Development Center for Medical Devices, National Taiwan University, Taipei, Taiwan
2011-2017
Director, NTU Yonglin Biomedical Engineering Center, National Taiwan University, Taipei, Taiwan
2008-present
Professor, Graduate Institute of Biomedical Electronics and Bioinformatics/Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan

Medical Device Industry and Healthcare Trend in Korea

Jae-young Ha
Senior Vice President,
Research & Business Development

AriBio Co.,Ltd.

＜Seminar content＞
Coming soon

＜Speaker Profile＞
Alma mater: Seoul National University
Diploma: Master and Bachelor of Science in Pharmacy
Professional qualification: Registered Pharmacist in Korea, Qualified Person Pharmacovigilance (QPPV) & Responsible Person (RP), European Medicine Agency (EMA), Medicine and Healthcare Regulatory Agency (MHRA) UK
A seasoned global entrepreneur and executive leader with over 40 years of strategic and operational experience in the pharmaceutical and medical device industries across the USA, UK, Europe, the Middle East, and Asia, including Korea. Recognized for proven expertise in research and development (R&D), clinical development, licensing, registration, and business development with global pharmaceutical companies, key opinion leader development, product launching, marketing and sales. Adept at establishing and managing businesses internationally, delivering sustainable growth, and driving strategic and research innovation in highly competitive markets.

Details on this Sesson (available only in Japanese) >>

*Titles omitted.

>> Check More Conference Program (Available only in Japanese)

Break down language barriers through translation application
available onsite

To enhance the understanding of international visitors during the conference, Show management has specially prepared translation application—Wordly. This translation application comes with multiple voice options for visitors to choose from, ensuring a great experience for overseas visitors!

*Please note that the number of translation application is limited and available on a first-come, first-served basis.